[6-K] IceCure Medical Ltd. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

IceCure Medical Ltd. (ICCM) filed a Form 6-K to furnish materials for a Special General Meeting of Shareholders scheduled for 1 September 2025. Shareholders of record at the close of business on 4 August 2025 are entitled to receive notice and vote. The filing attaches three exhibits: (i) Notice of Meeting, (ii) Proxy Statement, and (iii) Proxy Card. No financial statements, earnings figures, or transaction details are included. The 6-K is incorporated by reference into the company’s effective shelf (F-3) and equity compensation (S-8) registration statements.

Insights

Corporate Governance Analyst

TL;DR: Routine governance filing; limited market impact.

This 6-K merely distributes proxy materials for an upcoming special meeting and updates the company’s registration statements. No agenda items, strategic actions, or financial data are disclosed, so investors gain little insight into operations or valuation drivers. Unless the proxy statement (Exhibit 99.2) contains material proposals—which are not summarized here—the event is procedurally neutral.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

___________________

Form 6-K

___________________

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934

For the Month of July 2025 (Report No. 5)

Commission File Number: 001-40753

ICECURE MEDICAL Ltd.
(Translation of registrant’s name into English)

7 Ha’Eshel St., PO Box 3163
Caesarea, 3079504 Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒            Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is IceCure Medical Ltd.’s (the “Registrant”) Notice of Meeting, Proxy Statement and Proxy Card for the Special General Meeting of Shareholders to be held on Monday, September 1, 2025 (the “Meeting”).

Only shareholders of record who hold ordinary shares, no par value, of the Registrant at the close of business on Monday, August 4, 2025, will be entitled to notice of and to vote at the Meeting and any postponements or adjournments thereof.

Copies of the Notice of Meeting, Proxy Statement and Proxy Card for the Meeting are furnished herewith as Exhibits 99.1, 99.2 and 99.3, respectively.

This Report of Foreign Private Issuer on Form 6-K (the “Report”) is incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-267272 and 333-258660) and Form S-8 (File Nos. 333-270982, 333-264578, 333-262620 and 333-281587), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

Exhibits No.
99.1		Notice of Meeting for the Special General Meeting of Shareholders to be held on September 1, 2025.
99.2		Proxy Statement for the Special General Meeting of Shareholders to be held on September 1, 2025.
99.3		Proxy Card for the Special General Meeting of Shareholders to be held on September 1, 2025.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		IceCure Medical Ltd.
Date: July 28, 2025		By:		/s/ Eyal Shamir
				Name:		Eyal Shamir
				Title:		Chief Executive Officer

3

FAQ

When will ICCM's Special General Meeting take place?

The meeting is scheduled for Monday, 1 September 2025.

What is the record date for ICCM shareholders to vote?

Only holders of ICCM ordinary shares on Monday, 4 August 2025 may vote.

What documents did ICCM furnish with this Form 6-K?

The company attached the Notice of Meeting (Ex.99.1), Proxy Statement (Ex.99.2), and Proxy Card (Ex.99.3).

Does this 6-K contain any financial results or guidance for ICCM?

No, the report is limited to proxy materials and contains no financial statements or earnings data.